The central challenge for antibody therapies is shifting from discovery to targeting and delivery.

Source thesis

DCVC discusses antibody engineering that improves targeting and delivery, including computational structural and sequence models followed by laboratory testing. Manufacturability and stability are part of candidate selection; favourable clinical effects are goals requiring evidence, not established outcomes.